{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:48:15Z","timestamp":1740174495124,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf - Case Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40800-019-0105-8","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T18:21:26Z","timestamp":1571422886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fournier\u2019s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5746-8937","authenticated-orcid":false,"given":"Yasunori","family":"Nagano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi Kashiwagi","family":"Yakame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisae","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamaki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6881-3807","authenticated-orcid":false,"given":"Naoko Iwahashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"105_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/BF02554904","volume":"31","author":"JA Fournier","year":"1988","unstructured":"Fournier JA. Gangr\u00e8ne foudroyante de la verge (overwhelming gangrene). Sem Med. 1883. Dis Colon Rectum. 1988;31:984\u20138.","journal-title":"Dis Colon Rectum."},{"key":"105_CR2","doi-asserted-by":"publisher","first-page":"E407","DOI":"10.5489\/cuaj.2445","volume":"9","author":"M McCormack","year":"2015","unstructured":"McCormack M, Valiquette AS, Ismail S. Fournier\u2019s gangrene: a retrospective analysis of 26 cases in a Canadian hospital and literature review. Can Urol Assoc J. 2015;9:E407\u201310.","journal-title":"Can Urol Assoc J."},{"key":"105_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000445695","volume":"97","author":"MD Sorensen","year":"2016","unstructured":"Sorensen MD, Krieger JN. Fournier\u2019s gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97:249\u201359.","journal-title":"Urol Int"},{"key":"105_CR4","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1007\/s00268-005-0777-3","volume":"30","author":"H Yanar","year":"2006","unstructured":"Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, Baspinar I. Fournier\u2019s gangrene: risk factors and strategies for management. World J Surg. 2006;30:1750\u20134.","journal-title":"World J Surg"},{"key":"105_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/phar.1303","volume":"33","author":"S Riser Taylor","year":"2013","unstructured":"Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with Type 2 diabetes mellitus. Pharmacotherapy. 2013;33:984\u201399.","journal-title":"Pharmacotherapy."},{"key":"105_CR6","unstructured":"U.S. Food and Drug Administration. JARDIANCE 10\u00a0mg (Labeling-Medication Guide). In: Drugs@FDA. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s008lbl.pdf\n\n. Accessed 22 July 2019."},{"key":"105_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med."},{"key":"105_CR8","unstructured":"Cecilia-Chi WC, Lim-Tio S. Fournier\u2019s syndrome: a life threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus. In: Presented at: ADS ADEA Annual Scientific Meeting; August 24\u201326, 2016. Abstract no. 265."},{"key":"105_CR9","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dme.13508","volume":"34","author":"S Kumar","year":"2017","unstructured":"Kumar S, Costello AJ, Colman PG. Fournier\u2019s gangrene in a man on empagliflozin for treatment of type 2 diabetes. Diabet Med. 2017;34:1646\u20138.","journal-title":"Diabet Med"},{"key":"105_CR10","first-page":"100","volume":"35","author":"T Omer","year":"2018","unstructured":"Omer T, Dharan SS, Adler A. Sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin and Fournier\u2019s gangrene: a life threatening severe adverse outcome: case report. Diabet Med. 2018;35:100.","journal-title":"Diabet Med"},{"key":"105_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/1753-0407.12896","volume":"11","author":"CE Onder","year":"2019","unstructured":"Onder CE, Gursoy K, Kuskonmaz SM, Kocer U, Culha C. Fournier\u2019s gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes. 2019;11:348\u201350.","journal-title":"J Diabetes."},{"issue":"7","key":"105_CR12","doi-asserted-by":"publisher","first-page":"e5173","DOI":"10.7759\/cureus.5173","volume":"11","author":"G Elshimy","year":"2019","unstructured":"Elshimy G, Correa R, Alsayed M, Jyothinagaram S. Early presentation of a rare complication of sodium-glucose cotransporter-2 inhibitors 10 days after initiation: case report and literature review. Cureus. 2019;11(7):e5173. \nhttps:\/\/doi.org\/10.7759\/cureus.5173\n\n.","journal-title":"Cureus."},{"key":"105_CR13","unstructured":"U.S. Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. In: Drug safety and Availability. 2019. \nhttps:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes\n\n. Accessed 22 July 2019."},{"key":"105_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"105_CR15","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/dom.13255","volume":"20","author":"C Khouri","year":"2018","unstructured":"Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20:1531\u20134.","journal-title":"Diabetes Obes Metab"},{"key":"105_CR16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors. Ann Intern Med. 2019;170:764\u20139.","journal-title":"Ann Intern Med"},{"key":"105_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s005920050081","volume":"34","author":"L Luzi","year":"1997","unstructured":"Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol. 1997;34:239\u201344.","journal-title":"Acta Diabetol"}],"container-title":["Drug Safety - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-019-0105-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40800-019-0105-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40800-019-0105-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T23:25:06Z","timestamp":1602890706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40800-019-0105-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s40800-019-0105-8","relation":{},"ISSN":["2199-1162","2198-977X"],"issn-type":[{"type":"print","value":"2199-1162"},{"type":"electronic","value":"2198-977X"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"18 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yasunori Nagano, Naomi Kashiwagi Yakame, Hisae Aoki, Tamaki Yamakawa, and Naoko Iwahashi Kondo have no conflicts of interest that are directly relevant to the content of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent may be requested for review from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee Ministry of Health, Labor and Welfare and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"11"}}